Transaction details
Yu-Waye Chu, Chief Medical Officer at CytomX Therapeutics (NASDAQ: CTMX), sold 21,279 shares of common stock on March 17, 2026, at $6.423 per share. The total proceeds from the sale were $136,675. The sale price exceeded the company’s recent trading price of $4.78, which, despite a notable 613% return over the prior year, has pulled back recently.
Reason for the sale and holdings after transaction
The disposition was carried out to satisfy tax obligations arising from the vesting of restricted stock units. After completing the sale, Chu directly holds 189,446 shares of CytomX common stock, a figure that includes 149,833 restricted stock units.
Where investors can find additional analysis
InvestingPro provides additional context for interested investors, offering 11 ProTips that include analysis of CytomX’s financial condition and recent price movements.
Corporate financing and strategic moves
CytomX has announced a public offering of $250 million in common stock and pre-funded warrants, with the shares priced at $5.30 each. The company expects gross proceeds of $250 million before expenses. In addition, the underwriters have been granted a 30-day option to purchase up to an additional $37.5 million of common stock.
Analyst commentary
Following recent clinical updates, Jefferies increased its price target for CytomX to $16.00 from $8.00 and maintained a Buy rating. Oppenheimer raised its target to $12.00 from $10.00, citing promising trial data. Both firms noted the potential of CytomX’s drug candidates as a factor supporting their more positive outlooks.
Context from recent company communications
These developments come after CytomX’s Q4 2025 earnings call, which highlighted clinical progress but did not disclose specific financial metrics. The offered financing and the analyst updates reflect a company navigating funding for drug development alongside advancing clinical programs.
Note on scope - The article presents reported insider activity, company financing plans and analyst updates as disclosed by the company and firms cited. It does not add further financial metrics or projections beyond those statements.